Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

NCT00073216 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Clade B gag DNA/PLG and env DNA/PLG Microparticles
BIOLOGICAL: Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)